Lumida
/ATAI
⌘K
ATAI Life Sciences NV

ATAI Life Sciences NV

ATAI
$7.35USD↑+0.82%+0.06 today

MARKET CAP

2.7B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$7 – $7

52W RANGE

$3
$7

AI Summary

Stalk
StalkMedium

ATAI maintains its Stage 2 uptrend, but the active Bullish Exhaustion inflection pattern and recent pullback from highs signal waning upside momentum. Under a Speculative strategy, bullish engagement should be deferred to pullbacks into the rising 9/20 EMA support area for better asymmetry.

  • ↑$430.3M cash & equivalents funds operations through 2023
  • ↑11 clinical programs targeting mental health disorders
  • ↓Q2 revenue $1.7M, down 142.8% YoY, highlighting weak top line
Full analysis →

Buying

8

institutions

Selling

5

institutions

New Positions

3

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

BUY25.57 M134.78 M+18.74 M+457.0%0.00%
CA

Citadel Advisors LLC

Q2 2026

BUY2.52 M13.28 M+1.98 M+596.3%0.00%
MM

Millennium Management LLC

Q2 2026

SELL1.77 M9.33 M+-2.59 M-39.6%0.00%
WP

Woodline Partners LP

Q2 2026

SELL600.00 K3.16 M+-600.00 K-25.6%0.01%
MG

Man Group Plc

Q2 2026

SELL358.81 K1.89 M+-184.70 K-1.7%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

BUY273.35 K1.54 M+80.84 K+135.5%0.00%
RC

Rockefeller Capital Management L.P.

Q2 2026

BUY189.00 K996.03 K+10.00 K+57.2%0.00%
JH

Janus Henderson Group Plc

Q1 2026

BUYNEW158.80 K561.36 K+158.80 K+0.0%0.00%
EP

Eversept Partners, LP

Q2 2026

BUYNEW102.43 K539.81 K+102.43 K+0.0%0.03%
BA

Balyasny Asset Management L.P.

Q2 2026

BUYNEW50.25 K264.81 K+50.25 K+0.0%0.00%
AC

Aqr Capital Management LLC

Q2 2026

BUY34.67 K182.73 K+23.60 K+366.3%0.00%
PA

Point72 Asset Management, L.P.

Q2 2026

SELL0.000.00+-685.42 K-100.0%0.00%
BH

Brevan Howard Capital Management LP

Q2 2026

SELL0.000.00+-236.94 K-100.0%0.00%